Reinforcing properties of Pramipexole in normal and parkinsonian rats

Neurobiology of Disease

Volumn 49, Issue 1, 2013, Pages 79-86

  Engeln, Michel ^a,b   Ahmed, Serge H ^a,b   Vouillac, Caroline ^a,b   Tison, François ^a,b,c   Bezard, Erwan ^a,b,c   Fernagut, Pierre Olivier ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

6 OHDA; D2 3 agonist; Dopamine agonist; Dopamine replacement therapy; Parkinson's disease

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; PRAMIPEXOLE; TRANSCRIPTION FACTOR DELTA FOSB; TYROSINE 3 MONOOXYGENASE; ANTIPARKINSON AGENT; BENZOTHIAZOLE DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; FOSB PROTEIN, RAT; OXIDOPAMINE; PROTEIN C FOS;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CELLULAR DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; IMMUNOHISTOCHEMISTRY; MALE; NERVE CELL NETWORK; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REINFORCEMENT; SENSITIVITY ANALYSIS; SUBSTANTIA NIGRA; UPREGULATION; VENTRAL TEGMENTUM; ADDICTION; AGONISTS; ANIMAL; CORPUS STRIATUM; DRUG EFFECTS; DRUG SEEKING BEHAVIOR; DRUG SELF ADMINISTRATION; METABOLISM; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; CORPUS STRIATUM; DOPAMINE AGONISTS; DRUG-SEEKING BEHAVIOR; EXTINCTION, PSYCHOLOGICAL; IMMUNOHISTOCHEMISTRY; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSONIAN DISORDERS; PROTO-ONCOGENE PROTEINS C-FOS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; REINFORCEMENT SCHEDULE; SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS;

EID: 84866512098     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.08.005     Document Type: Article

References (90)

1. Ahmed S.H. The science of making drug-addicted animals. Neuroscience 2011.
2. Ahmed S.H., Cador M. Dissociation of psychomotor sensitization from compulsive cocaine consumption. Neuropsychopharmacology 2006, 31:563-571.
3. Ahmed S.H., Koob G.F. Cocaine- but not food-seeking behavior is reinstated by stress after extinction. Psychopharmacology (Berl) 1997, 132:289-295.
4. Anthony J.C., et al. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp. Clin. Psychopharmacol. 1994, 2:244-268.
5. Belin D., et al. High-novelty-preference rats are predisposed to compulsive cocaine self-administration. Neuropsychopharmacology 2011, 36:569-579.
6. Berthet A., et al. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. J. Neurosci. 2009, 29:4829-4835.
7. Berton O., et al. Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease. Biol. Psychiatry 2009, 66:554-561.
8. Bezard E., et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 2001, 21:6853-6861.
9. Bezard E., et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med. 2003, 9:762-767.
10. Bonuccelli U., et al. Role of dopamine receptor agonists in the treatment of early Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15(Suppl. 4):S44-S53.
11. Bordet R., et al. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:3363-3367.
12. Caille S., et al. Total neurochemical lesion of noradrenergic neurons of the locus ceruleus does not alter either naloxone-precipitated or spontaneous opiate withdrawal nor does it influence ability of clonidine to reverse opiate withdrawal. J. Pharmacol. Exp. Ther. 1999, 290:881-892.
13. Caine S.B., et al. D3 receptor test in vitro predicts decreased cocaine self-administration in rats. Neuroreport 1997, 8:2373-2377.
14. Cantin L., et al. Cocaine is low on the value ladder of rats: possible evidence for resilience to addiction. PLoS One 2010, 5:e11592.
15. Chang W.L., et al. Disparate effects of pramipexole on locomotor activity and sensorimotor gating in Sprague-Dawley rats. Pharmacol. Biochem. Behav. 2011, 99:634-638.
16. Charron G., et al. Endogenous morphine-like compound immunoreactivity increases in parkinsonism. Brain 2011, 134:2321-2338.
17. Chiodo K.A., Roberts D.C. Decreased reinforcing effects of cocaine following 2 weeks of continuous D-amphetamine treatment in rats. Psychopharmacology (Berl) 2009, 206:447-456.
18. Collins G.T., Woods J.H. Drug and reinforcement history as determinants of the response-maintaining effects of quinpirole in the rat. J. Pharmacol. Exp. Ther. 2007, 323:599-605.
19. Collins G.T., et al. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J. Pharmacol. Exp. Ther. 2005, 314:310-319.
20. Collins G.T., et al. Proerectile effects of dopamine D2-like agonists are mediated by the D3 receptor in rats and mice. J. Pharmacol. Exp. Ther. 2009, 329:210-217.
21. Collins G.T., et al. Effects of pramipexole on the reinforcing effectiveness of stimuli that were previously paired with cocaine reinforcement in rats. Psychopharmacology (Berl) 2011.
22. Corbett D., Wise R.A. Intracranial self-stimulation in relation to the ascending dopaminergic systems of the midbrain: a moveable electrode mapping study. Brain Res. 1980, 185:1-15.
23. Cornelius J.R., et al. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 2010, 33:81-87.
24. Damier P., et al. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999, 122(Pt. 8):1437-1448.
25. Davie M. Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. J. Neuropsychiatry Clin. Neurosci. 2007, 19:473-474.
26. Deroche-Gamonet V., et al. Evidence for addiction-like behavior in the rat. Science 2004, 305:1014-1017.
27. Dobi A., et al. Cocaine-induced plasticity in the nucleus accumbens is cell specific and develops without prolonged withdrawal. J. Neurosci. 2011, 31:1895-1904.
28. Doherty J.M., Frantz K.J. Heroin self-administration and reinstatement of heroin-seeking in adolescent vs. adult male rats. Psychopharmacology (Berl) 2011.
29. Dunnett S.B., Lelos M. Behavioral analysis of motor and non-motor symptoms in rodent models of Parkinson's disease. Prog. Brain Res. 2010, 184:35-51.
30. Ersche K.D., et al. Response perseveration in stimulant dependence is associated with striatal dysfunction and can be ameliorated by a D(2/3) receptor agonist. Biol. Psychiatry 2011, 70:754-762.
31. Evans A.H., et al. Impulsive and compulsive behaviors in Parkinson's disease. Mov. Disord. 2009, 24:1561-1570.
32. Fasano S., et al. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21824-21829.
33. Faure A., et al. Lesion to the nigrostriatal dopamine system disrupts stimulus-response habit formation. J. Neurosci. 2005, 25:2771-2780.
34. Faure A., et al. Dopamine agonists increase perseverative instrumental responses but do not restore habit formation in a rat model of Parkinsonism. Neuroscience 2010, 168:477-486.
35. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114(Pt. 5):2283-2301.
36. Frank M.J., et al. By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science 2004, 306:1940-1943.
37. Giovannoni G., et al. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J. Neurol. Neurosurg. Psychiatry 2000, 68:423-428.
38. Hall J., et al. Involvement of the central nucleus of the amygdala and nucleus accumbens core in mediating Pavlovian influences on instrumental behaviour. Eur. J. Neurosci. 2001, 13:1984-1992.
39. Hamidovic A., et al. Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. J. Clin. Psychopharmacol. 2008, 28:45-51.
40. Holman A.J. Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. J. Gambl. Stud. 2009, 25:425-431.
41. Hope B.T., et al. Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron 1994, 13:1235-1244.
42. Hummel M., Unterwald E.M. D1 dopamine receptor: a putative neurochemical and behavioral link to cocaine action. J. Cell. Physiol. 2002, 191:17-27.
43. Koob G.F., Nestler E.J. The neurobiology of drug addiction. J. Neuropsychiatry Clin. Neurosci. 1997, 9:482-497.
44. Lawrence A.D., et al. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?. Lancet Neurol. 2003, 2:595-604.
45. Le Foll B., et al. Dopamine D3 receptor agents as potential new medications for drug addiction. Eur. Psychiatry 2000, 15:140-146.
46. Le Foll B., et al. The dopamine D3 receptor and drug dependence: effects on reward or beyond?. Neuropharmacology 2005, 49:525-541.
47. Lenoir M., Ahmed S.H. Heroin-induced reinstatement is specific to compulsive heroin use and dissociable from heroin reward and sensitization. Neuropsychopharmacology 2007, 32:616-624.
48. Lenoir M., Ahmed S.H. Supply of a nondrug substitute reduces escalated heroin consumption. Neuropsychopharmacology 2008, 33:2272-2282.
49. Lindner M.D., et al. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Behav. Brain Res. 1999, 102:1-16.
50. Marcellino D., et al. Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J. Biol. Chem. 2008, 283:26016-26025.
51. Mash D.C., Staley J.K. D3 dopamine and kappa opioid receptor alterations in human brain of cocaine-overdose victims. Ann. N. Y. Acad. Sci. 1999, 877:507-522.
52. Mihindou C., et al. Preclinical validation of a novel cocaine exposure therapy for relapse prevention. Biol. Psychiatry 2011, 70:593-598.
53. Molina J.A., et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?. Mov. Disord. 2000, 15:869-872.
54. Morgan D., et al. Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration. Nat. Neurosci. 2002, 5:169-174.
55. Morgan D., et al. Rapid and persistent sensitization to the reinforcing effects of cocaine. Neuropsychopharmacology 2006, 31:121-128.
56. Nader M.A., Mach R.H. Self-administration of the dopamine D3 agonist 7-OH-DPAT in rhesus monkeys is modified by prior cocaine exposure. Psychopharmacology (Berl) 1996, 125:13-22.
57. Neisewander J.L., et al. Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior. Neuropsychopharmacology 2004, 29:1479-1487.
58. Nomura Y., Segawa T. Ontogenesis of rearing and stereotypy responses to apomorphine in the rat. J. Pharmacobiodyn. 1980, 3:69-73.
59. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2009, Elsevier.
60. Pellegrino L.J., et al. A Stereotaxic Atlas of the Rat Brain 1979, Plenum Press, New York.
61. Pioli E.Y., et al. Asymmetrically lesioned mesencephalon in healthy rodents: call for caution. Brain Res. 2004, 1022:251-253.
62. Pioli E.Y., et al. Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in rats. Neuroscience 2008, 153:1213-1224.
63. Rabinak C.A., Nirenberg M.J. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch. Neurol. 2010, 67:58-63.
64. Rascol O., et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 2000, 342:1484-1491.
65. Richardson N.R., Roberts D.C. Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J. Neurosci. Methods 1996, 66:1-11.
66. Roberts D.C. Breaking points on a progressive ratio schedule reinforced by intravenous apomorphine increase daily following 6-hydroxydopamine lesions of the nucleus accumbens. Pharmacol. Biochem. Behav. 1989, 32:43-47.
67. Roberts D.C., Koob G.F. Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in rats. Pharmacol. Biochem. Behav. 1982, 17:901-904.
68. Roberts D.C., et al. Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens. Pharmacol. Biochem. Behav. 1980, 12:781-787.
69. Rodriguez Diaz M., et al. Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease. Behav. Brain Res. 2001, 122:79-92.
70. Rodriguez M., et al. Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in parkinson's disease. Exp. Neurol. 2001, 169:163-181.
71. Saka E., et al. Compartmental changes in expression of c-Fos and FosB proteins in intact and dopamine-depleted striatum after chronic apomorphine treatment. Brain Res. 1999, 825:104-114.
72. Schott B.H., et al. Ageing and early-stage Parkinson's disease affect separable neural mechanisms of mesolimbic reward processing. Brain 2007, 130:2412-2424.
73. Schultz W. Predictive reward signal of dopamine neurons. J. Neurophysiol. 1998, 80:1-27.
74. Schwarting R.K., Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 1996, 50:275-331.
75. Self D.W., et al. Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists. Science 1996, 271:1586-1589.
76. Self D.W., et al. Self-administration of the D1 agonist SKF 82958 is mediated by D1, not D2, receptors. Psychopharmacology (Berl) 1996, 123:303-306.
77. Thobois S., et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010, 133:1111-1127.
78. Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 1971, 367:95-122.
79. van Eimeren T., et al. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?. Neuropsychopharmacology 2009, 34:2758-2766.
80. Volkow N.D., et al. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am. J. Psychiatry 1999, 156:1440-1443.
81. Voon V., et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol. 2009, 8:1140-1149.
82. Weintraub D., et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol. 2010, 67:589-595.
83. Westin J.E., et al. Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease. Eur. J. Neurosci. 2001, 14:1171-1176.
84. Wiecki T.V., Frank M.J. Neurocomputational models of motor and cognitive deficits in Parkinson's disease. Prog. Brain Res. 2010, 183:275-297.
85. Wise R.A. Roles for nigrostriatal-not just mesocorticolimbic-dopamine in reward and addiction. Trends Neurosci. 2009, 32:517-524.
86. Wise R.A., et al. Bromocriptine self-administration and bromocriptine-reinstatement of cocaine-trained and heroin-trained lever pressing in rats. Psychopharmacology (Berl) 1990, 100:355-360.
87. Woolverton W.L., et al. Intravenous self-administration of dopamine receptor agonists by rhesus monkeys. J. Pharmacol. Exp. Ther. 1984, 230:678-683.
88. Ye Z., et al. Pramipexole modulates the neural network of reward anticipation. Hum. Brain Mapp. 2010.
89. Yin H.H., et al. The role of the dorsomedial striatum in instrumental conditioning. Eur. J. Neurosci. 2005, 22:513-523.
90. Yokel R.A., Wise R.A. Amphetamine-type reinforcement by dopaminergic agonists in the rat. Psychopharmacology (Berl) 1978, 58:289-296.